Overview

PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46

Status:
Not yet recruiting
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
The tumor stroma supports tumor growth, promotes tumor aggressiveness and metastatic potential. Stroma targeting approaches have become an attractive goal in research and industry. Braking the tumor stroma barrier may make tumor cells more accessible for pharmacologic, immunologic, radioactive or cell-based therapies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)